BioSpace News Archive

A former CEO of Vyera and other activist investors are pushing a slate of new company directors who would steer control of Phoenixus and Vyera away from Shkreli.

HHS issued their announcement, saying, “Americans who have been fully vaccinated do not need a booster shot at this time.”

It was based on data from the APOLLO trial showing the drug significantly decreased the risk of progression or death by 37% compared to dexamethasone alone.

The Viral Antigens market was valued at US$101.41 million in 2019 and is projected to reach US$ 236.80 million by 2027; it is expected to grow at a CAGR of 11.0% during 2020–2027.

The antacid market is expected to reach US$ 11,666.83 million in 2027 from US$ 8,547.97 million in 2019. The market is estimated to grow with a CAGR of 4.0% from 2020-2027.

Novo Nordisk will take over Prothena’s wholly-owned subsidiary and gain full global intellectual property rights and other related rights for the latter’s ATTR amyloidosis business and pipeline.

The hospital mobile X-Ray market was valued at US$ 1,604.92 million in 2019 and it is projected to reach US$ 3,479.79 million by 2027; it is expected to grow at a CAGR of 10.2% during 2020–2027.

The evolution of the urinary self-catheters market is underpinned in large part to the need for devices with high safety profile and ability to mimic the natural micturition.

The increasing cases of infectious diseases are a prime factor augmenting the growth of the global digital PCR and real-time PCR market during the forecast period set between 2020 and2030.

AB Science SA announced that it has been informed by the French National Agency that the measures proposed by AB Science to reinforce patient safety in masitinib trials are acceptable to allow resumption of enrollment in its three ongoing studies; namely, the phase 3 study in mastocytosis, the phase 3 study in amyotrophic lateral sclerosis, and the phase 2 study in COVID-19.